Interleukin Genetics introduced a Bone Health Genetic Test designed to detect genetic patterns associated with the development of osteoporosis-related outcomes. The test determines an individual's risk for developing vertebral or spinal fractures and low bone mineral density. According to the company, knowing one's genetic risk could allow an individual to take action toward building optimal bone health.
The Bone Health Genetic Test was developed following the completion of a 2,500-person clinical study conducted by Interleukin Genetics in collaboration with a university partner. Recently released data from the study that showed variations in the interleukin 1 beta, vitamin D receptor, and estrogen receptor 1 genes were strongly associated with risk of spine fracture or low bone mineral density. Association between these variations and vertebral fracture or bone mineral density was determined by logistic regression analysis with adjustment for age, BMI, estrogen use, and other covariates.
The Bone Health Genetic Test analyzes gene variations that were identified from the study as showing statistically significant increased risk for spinal fracture and low bone mineral density and provides risk information beyond that provided by traditional risk factors such as age and BMI, in the assessment of an individual's overall risk for bone health.